Acorda Therapeutics, Inc. (ACOR)
| Market Cap | 11.38M |
| Revenue (ttm) | 122.74M |
| Net Income (ttm) | -95.02M |
| Shares Out | 24.28M |
| EPS (ttm) | -8.22 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 19,635 |
| Open | 0.461 |
| Previous Close | 0.461 |
| Day's Range | 0.450 - 0.480 |
| 52-Week Range | 0.280 - 4.990 |
| Beta | 0.47 |
| Analysts | Buy |
| Price Target | 10.20 (+2,076.7%) |
| Earnings Date | Aug 4, 2022 |
About ACOR
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for t... [Read more...]
Financial Performance
In 2021, ACOR's revenue was $129.07 million, a decrease of -15.62% compared to the previous year's $152.97 million. Losses were -$103.95 million, 4.38% more than in 2020.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for ACOR stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 2,076.70% from the latest price.
News
Acorda Therapeutics Reports Second Quarter 2022 Financial Results
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2022 Financial Results
Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2022 Update: Webcast/Conference Call Scheduled for August 4, 2022
Why Acorda Therapeutics Shares Gaining Today?
Acorda Therapeutics Inc (NASDAQ: ACOR) announced that Esteve Pharmaceuticals GmbH launched INBRIJA 33 mg (levodopa inhalation powder, hard capsules) in Germany. INBRIJA is indicated in the EU for the i...
Esteve Launches INBRIJA® in Germany
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that Esteve Pharmaceuticals GmbH has launched INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) in G...
Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America
ARDSLEY, N.Y. & PANAMA CITY--(BUSINESS WIRE)--Acorda Therapeutics and Biopas Laboratories Announce Agreement to Commercialize INBRIJA® in Latin America
Acorda Therapeutics Reports First Quarter 2022 Financial Results
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2022 Financial Results
Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda First Quarter 2022 Update: Webcast/Conference Call Scheduled for May 11, 2022
Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2021 Update: Webcast/Conference Call Scheduled for March 9, 2022
Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
John Varian Joins Acorda Therapeutics Board of Directors
ARDSLEY, N.Y.--(BUSINESS WIRE)--John Varian joins Acorda Therapeutics Board of Directors
Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Third Quarter 2021 Financial Results, Additions to Leadership Team
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Germany
Earnings Outlook For Acorda Therapeutics
Acorda Therapeutics (NASDAQ:ACOR) is set to give its latest quarterly earnings report on Tuesday, 2021-11-09. Here's what investors need to know before the announcement.
Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Third Quarter 2021 Update: Webcast Scheduled for November 9, 2021
Acorda Therapeutics Announces Corporate Restructuring, Management Changes
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Corporate Restructuring, Management Changes
Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates
Acorda (ACOR) delivered earnings and revenue surprises of -9.57% and 6.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Acorda Therapeutics Reports Second Quarter 2021 Financial Results
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2021 Financial Results
Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2021 Update: Webcast/Conference Call Scheduled for August 5, 2021
Will Acorda Therapeutics (ACOR) Report Negative Q2 Earnings? What You Should Know
Acorda (ACOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Acorda Therapeutics Shares Gains On Spain Distribution Pact For Parkinson's Med
Acorda Therapeutics Inc (NASDAQ: ACOR) has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A. to commercialize Inbrija 33 mg (levodopa inhalation powder, hard capsules) in ...
Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Agreement to Commercialize INBRIJA® in Spain
Acorda Therapeutics Announces Repayment of Convertible Senior Notes
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Repayment of Convertible Senior Notes
Acorda Therapeutics (ACOR) Reports Q1 Loss, Tops Revenue Estimates
Acorda (ACOR) delivered earnings and revenue surprises of 3.15% and 30.30%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Acorda Therapeutics Reports First Quarter 2021 Financial Results
ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2021 Financial Results